Hat mitgewirkt an:
-
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings
-
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
-
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
-
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity